Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.

Ebright MI, Russo GA, Gupta A, Subramaniam RM, Fernando HC, Kachnic LA.

J Thorac Cardiovasc Surg. 2013 Mar;145(3):709-15. doi: 10.1016/j.jtcvs.2012.12.024. Epub 2013 Jan 12.

2.

CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.

Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, Suy S, Yousefi S, Gutierrez CJ, Chang T, Banovac F, Anderson ED, Esposito G, Collins BT.

J Hematol Oncol. 2010 Feb 4;3:6. doi: 10.1186/1756-8722-3-6.

3.

Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.

Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.

Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1033-9. doi: 10.1016/j.ijrobp.2009.09.081. Epub 2010 May 14.

PMID:
20472359
4.

Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.

Dunlap NE, Yang W, McIntosh A, Sheng K, Benedict SH, Read PW, Larner JM.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1071-7. doi: 10.1016/j.ijrobp.2012.01.088. Epub 2012 Aug 14.

PMID:
22898383
5.

FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.

Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC.

Lung Cancer. 2007 May;56(2):229-34. Epub 2007 Mar 13.

PMID:
17353064
6.

Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.

Essler M, Wantke J, Mayer B, Scheidhauer K, Bundschuh RA, Haller B, Astner ST, Molls M, Andratschke N.

Strahlenther Onkol. 2013 Jun;189(6):495-501. doi: 10.1007/s00066-013-0310-9. Epub 2013 Apr 24.

PMID:
23609133
7.

Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.

Satoh Y, Nambu A, Onishi H, Sawada E, Tominaga L, Kuriyama K, Komiyama T, Marino K, Aoki S, Araya M, Saito R, Maehata Y, Oguri M, Araki T.

Eur J Radiol. 2012 Nov;81(11):3530-4. doi: 10.1016/j.ejrad.2011.11.047. Epub 2011 Dec 16.

PMID:
22178287
8.

Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.

Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.

Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1009-14. doi: 10.1510/icvts.2009.227538. Epub 2010 Mar 2.

9.

18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.

Toba H, Sakiyama S, Otsuka H, Kawakami Y, Takizawa H, Kenzaki K, Kondo K, Tangoku A.

Interact Cardiovasc Thorac Surg. 2012 Nov;15(5):859-64. doi: 10.1093/icvts/ivs368. Epub 2012 Aug 21.

10.

Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.

Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, Brade A, Cho J, Sun A, Bissonnette JP, Bezjak A.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):967-73. doi: 10.1016/j.ijrobp.2010.12.039. Epub 2011 Mar 4.

PMID:
21377293
11.

Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.

Lancet Oncol. 2012 Aug;13(8):802-9. doi: 10.1016/S1470-2045(12)70242-5. Epub 2012 Jun 22.

PMID:
22727222
12.

Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.

Haidar YM, Rahn DA 3rd, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP.

Ther Adv Respir Dis. 2014 Feb;8(1):3-12. doi: 10.1177/1753465813512545. Epub 2013 Dec 10.

PMID:
24334338
14.

Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.

Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N.

Clin Lung Cancer. 2008 Jul;9(4):217-21. doi: 10.3816/CLC.2008.n.032.

PMID:
18650169
15.

Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer.

Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, Kim JH.

Ann Thorac Surg. 2011 Nov;92(5):1826-32; discussion 1832. doi: 10.1016/j.athoracsur.2011.07.005. Epub 2011 Oct 31.

PMID:
22051278
16.

Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.

Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1558-65. doi: 10.1016/j.ijrobp.2011.10.035. Epub 2012 May 7.

17.

Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.

Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y, Oku Y, Ohashi T, Sanuki N, Mizuno T, Ozawa Y.

Lung Cancer. 2013 Mar;79(3):248-53. doi: 10.1016/j.lungcan.2012.11.008. Epub 2012 Dec 11.

PMID:
23246123
18.

Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment.

Hamamoto Y, Kataoka M, Yamashita M, Nogami N, Sugawara Y, Kozuki T, Sawada S, Suehisa H, Shinohara S, Nakajima N, Shinkai T.

Jpn J Radiol. 2012 Oct;30(8):671-5. doi: 10.1007/s11604-012-0107-2. Epub 2012 Jul 20.

PMID:
22836906
19.

Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?

Clarke K, Taremi M, Dahele M, Freeman M, Fung S, Franks K, Bezjak A, Brade A, Cho J, Hope A, Sun A.

Radiother Oncol. 2012 Jul;104(1):62-6. doi: 10.1016/j.radonc.2012.04.019. Epub 2012 Jun 9.

PMID:
22682749
20.

Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.

Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e551-5. doi: 10.1016/j.ijrobp.2012.01.012. Epub 2012 Mar 13.

PMID:
22417800
Items per page

Supplemental Content

Write to the Help Desk